Brown Brothers Harriman & CO Aerie Pharmaceuticals Inc Transaction History

Brown Brothers Harriman & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$12.0 - $16.13 $2,040 - $2,742	-170 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$11.84 - $25.52 $2,012 - $4,338	170 New	170 $2,000
Q1 2018 May 14, 2018	SELL	$51.15 - $61.0 $5,779 - $6,893	-113 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$50.85 - $65.1 $5,746 - $7,356	113	113 $7,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Brown Brothers Harriman & CO, based on Form 13F filings with the SEC.

Stay updated on Brown Brothers Harriman & CO with notifications on news.